Drug intelligence / Profile preview

SP-12008

Development stage: Preclinical
Lead developer: Spherium Biomed

Overview

SP-12008 is a discovery-stage therapeutic candidate developed by Spherium Biomed for the treatment of Graft-versus-Host Disease (GvHD). Spherium Biomed was originally established as a joint venture between Ferrer and Janus Pharmaceuticals to manage and advance R&D projects. In 2018, Ferrer acquired full control of Spherium Biomed and integrated its pipeline. SP-12008 is positioned within the discovery phase, and specific details regarding its molecular target, modality, and mechanism of action have not been publicly disclosed in available clinical or corporate literature.

Beyond the preview

Go deeper on SP-12008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SP-12008.

Explore the full profile